A2BIO
Startup
A2BIO
Description
A2bio develops T cells that target the loss of genetic material in tumors designed for enabling the selective killing of tumor cells while leaving normal cells unharmed.
A2BIO
Address
United States
Contact
Description
A2bio develops T cells that target the loss of genetic material in tumors designed for enabling the selective killing of tumor cells while leaving normal cells unharmed.
Matchmaking
Connect with A2BIO
This entity is yours?
Update informationPosition on the value chain
With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.
Bio-resources and biobanking
- Cells, tissues and humanized xeno-organs
- Biosamples
- Viral, phage or bacterial specimen
Identification of biotherapies
- Target identification
- Target validation
- Screening
Drug design
- Drug assessment
- Drug engineering
- In vitro preclinical studies
Clinical validation
- Clinical trials
- In vivo preclinical validation
- Pre-industrial scale production
Production
- Upstream processes
- Downstream processes
- Quality control
Market access
- CE mark / market authorisation
- Payment / Reimbursement
- Care pathways